A team of researchers has found new insight into why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings may help improve future ways to deliver ...

Biomarker testing is vital for all patients with lung cancer, especially younger individuals who have higher rates of ...

A team of researchers from Moffitt Cancer Center has found new insight into why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings, published ...

A team of researchers from Moffitt Cancer Center has found new insight into why some lung cancer patients do not benefit from ...

A community bowling fundraiser is raising money to help a local man cover cancer treatment and travel expenses.

Sino-American biotech BeiGene (Nasdaq: ONC; HKEX 06160) today announced that the European Commission has approved Tevimbra ...

Predictors of longer postdiscontinuation progression-free survival include complete/partial response, longer treatment duration.

OmRx Oncology, or "OmRx," a clinical-stage biopharmaceutical venture dedicated to expanding access to cancer immunotherapy worldwide, today announced the initiation of a Phase 2 clinical trial of its ...

Raymond Osarogiagbon, MD, discusses innovative strategies for improving lung cancer screening, including artificial intelligence (AI) tools and simplified eligibility criteria.

A team of researchers from Moffitt Cancer Center has found new insight into why some lung cancer patients do not benefit from tumor-infiltrating ...

Targeting clonal antigens and circumventing dysfunctional states may be important for conferring clinical responses to TIL therapy.

First patient dosed in study investigating roginolisib + dostarlimab +/- docetaxel in patients with NSCLC who have progressed on prior immunotherapy/chemo Study will evaluate ...